Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing & Reimbursement

Set Alert for Pricing & Reimbursement

BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More

Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.

BIO Deals

ASCO: Legend/J&J Explore Carvykti In Community

The companies presented data from CARTITUDE-4 in functional high-risk disease, which has a poorer prognosis, while they are also piloting a program to expand Carvykti’s geographic reach.

ASCO CAR-T

Could Combining Strategies Be A Way Forward To Pay For Gene Therapies?

A report by ICER and Tufts Medical Center’s NEWDIGS said a single strategy cannot adequately address payment challenges for all payers.

Gene Therapy Market Access

The Looming US Election Weighs On The Minds Of Pharma

The US presidential election in November could mean IRA expansion from a Biden win, but a Trump victory also brings uncertainty.

Politics Policy

Underperforming Launches Reflect A New Era Of Payer Headwinds, IQVIA Says

US drug launches are underperforming historical metrics across nearly all therapeutic areas, according to IQVIA, which said limiting payer policies are the key factor.

Launches Market Access

Hypertension To Mental Health Drugs: Indian Firms Supplied Bulk Of Rx Volume In US

Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.

Commercial Generic Drugs

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

IQVIA’s latest usage and spending trends report forecasts US obesity market will grow to $35bn by 2028, while the two leading GLP-1 agonists have already posted eye-popping sales growth.

Pricing Debate Metabolic Disorders

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

BioNTech and the UK government's alliance to bring personalized cancer immunotherapy to patients is making progress, but the National Health Service has to show it can deliver on clinical trials recruitment.

Companies Commercial

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Novo raises its top- and bottom-line guidance as it prioritizes volume over price.

Commercial Companies

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Business Strategies Clinical Trials

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.

Biosimilars Commercial

Explained: How China’s Public Payer Wants To Define Innovative Drugs

China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.

China Research & Development

Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist

The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.

EU Legislative Reform Market Access

Why Global Pull Incentives Matter For AMR Drugs

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Infectious Diseases Reimbursement

ITF Has A Fight On Its Hands In Duchenne

The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.

Approvals Commercial

Novartis Measures Malaria Success On Impact Rather Than Money

The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.

Rwanda Market Access
See All
UsernamePublicRestriction

Register